hydroxychloroquine has been researched along with Shock, Cardiogenic in 3 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Shock, Cardiogenic: Shock resulting from diminution of cardiac output in heart disease.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The novel coronavirus disease 2019, otherwise known as COVID-19, is a global pandemic with primary respiratory manifestations in those who are symptomatic." | 2.66 | Approach to Acute Cardiovascular Complications in COVID-19 Infection. ( Abdalla, M; Anstey, DE; Fried, JA; Givens, RC; Karmpaliotis, D; Kirtane, AJ; Kodali, SK; Kumaraiah, D; Leon, MB; Masoumi, A; Rabbani, LE; Ranard, LS; Sayer, G; Schwartz, A; Takeda, K; Uriel, N, 2020) |
| "A ventricular fibrillation was treated with external cardiac massage." | 1.34 | [Treatment of hydroxychloroquine poisoning with extracorporeal circulation]. ( Blin, D; Derderian, F; Durand, M; Gonthier, YT; Mongenot, F, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Ranard, LS | 1 |
| Fried, JA | 1 |
| Abdalla, M | 1 |
| Anstey, DE | 1 |
| Givens, RC | 1 |
| Kumaraiah, D | 1 |
| Kodali, SK | 1 |
| Takeda, K | 1 |
| Karmpaliotis, D | 1 |
| Rabbani, LE | 1 |
| Sayer, G | 1 |
| Kirtane, AJ | 1 |
| Leon, MB | 1 |
| Schwartz, A | 1 |
| Uriel, N | 1 |
| Masoumi, A | 1 |
| Montejo, M | 1 |
| Goikoetxea, J | 1 |
| Mularoni, A | 1 |
| Blanco, MJ | 1 |
| Gaafar, A | 1 |
| Boado, MV | 1 |
| Marín, M | 1 |
| Aramendi, JI | 1 |
| Mongenot, F | 1 |
| Gonthier, YT | 1 |
| Derderian, F | 1 |
| Durand, M | 1 |
| Blin, D | 1 |
1 review available for hydroxychloroquine and Shock, Cardiogenic
| Article | Year |
|---|---|
Approach to Acute Cardiovascular Complications in COVID-19 Infection.
Topics: Acute Coronary Syndrome; Anti-Bacterial Agents; Antiviral Agents; Arrhythmias, Cardiac; Azithromycin | 2020 |
2 other studies available for hydroxychloroquine and Shock, Cardiogenic
| Article | Year |
|---|---|
[Tropheryma wipplei endocarditis: a report of 3 cases].
Topics: Actinomycetales Infections; Anti-Bacterial Agents; Anticoagulants; Doxycycline; Drug Therapy, Combin | 2013 |
[Treatment of hydroxychloroquine poisoning with extracorporeal circulation].
Topics: Adult; Antidotes; Bromazepam; Charcoal; Coma; Combined Modality Therapy; Diazepam; Drug Overdose; Ep | 2007 |